TrialNature medicine2024

Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial.

Johannes F E Mann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.